|Day Low/High||17.25 / 17.83|
|52 Wk Low/High||16.63 / 35.45|
UBS lowers its price target on Pfizer to $37 a share and maintains its neutral rating on the stock.
Buy Mylan at the market and add to positions on weakness to its monthly value level at $15.75. The weekly chart will be positive on a weekly close above its five-week modified moving average at $19.43.
The company generates increased sales from its existing suite of generic drugs as well as some new product launches.
Strong demand for its lineup of generic drugs and more to come from additional upcoming launches as it moves toward closing its deal with Pfizer's PFE Upjohn business all helped boost third-quarter sales and earnings for Mylan.
Investors must understand that the narrative around trade with China has evolved as the two sides work on a 'Phase One' mini-trade deal, but this is about much more than that.
HERTFORDSHIRE, England and PITTSBURGH, Nov. 5, 2019 /PRNewswire/ -- Mylan N.
U.S. stock futures rise a day after the three major U.S. benchmark indexes posted record closing highs on positive trade developments between the U.S. and China and strong corporate earnings; Uber posts $1.2 billion loss but sees profitability in 2021; Shake Shacks sinks on a weak same-store sales forecast.
Disney, Qualcomm and Square are among 75 key reports we are watching.
HERTFORDSHIRE, England and PITTSBURGH, Oct. 24, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.
Study provides data on YUPELRI when administered with formoterol in patients with COPD
Mylan called the settlement "the right course of action."
HERTFORDSHIRE, England, and PITTSBURGH, Sept. 27, 2019 /PRNewswire/ -- Mylan N.
Pfizer shares edged higher Friday after the company posted promising results from trials of a drug it's developing to treat patients with moderate-to-severe eczema.
So many companies -- like Netflix, Facebook and Johnson & Johnson -- are not trading on earnings per share, but on factors that are nearly impossible to quantify.
HERTFORDSHIRE, England and PITTSBURGH, Sept. 17, 2019 /PRNewswire/ -- Mylan N.
Antares Pharma and Encana are on our radar today.
There has been an EpiPen shortage in the U.S., Europe and Canada, thanks to manufacturing delays at Pfizer.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BLX, CRMD, DHX, FTAI, HCP, MHO, MRC, XPO Downgrades: AINC, ARW, BPY, CRAY, EARN, FLR, HRTG, IDSY, MYL, PATK, PXLW, TRQ, TWI, WMS Initiations: BCDA, USX Read on to get TheStreet Quant Ratings' detailed report:
NEW YORK, July 29, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Mylan N.
The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.
Pfizer reports earnings and announces a massive tie-up with Mylan, sending shares of the latter shooting higher.
Jim Cramer's eyeing Merck and Pfizer. Here's why.
What new management means for Mylan shareholders moving forward.
Mylan and Pfizer agreed to combine their off-patent drug businesses in an all-stock deal that will create a new company based in the United States.
Jim Cramer tackles Starbucks, the Federal Reserve, earnings and Mylan ahead of a week filled with potentially market-moving headlines.
Pfizer is in talks to merge its off-patent drug operation with Mylan.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.